Ben Robert Dickie

Ben Robert Dickie

Auto-generated profile, based on publicly available information

Ben Robert Dickie

Geoffrey Jefferson Brain Research Centre, Manchester Academic Health Science Centre, Northern Care Alliance & University of Manchester, Manchester, UK

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2021 in Frontiers in Neuroscience
Verified
Journal Article
Open access
NKNatalia Kyrtata
Natalia Kyrtata
HEHedley C. A. Emsley
Hedley C. A. Emsley
OSOli Sparasci
Oli Sparasci
LPLaura M. Parkes
Laura M. Parkes
BDBen R. Dickie
Ben R. Dickie
Introduction: Alzheimer's disease (AD) is characterized by cerebral glucose hypometabolism. Hypometabolism may be partly due to reduced glucose transport at the blood-brain barrier (BBB) and across astrocytic and neuronal cell membranes. Glucose transporters (GLUTs) are integral membrane proteins responsible for moving glucose from the bloodstream to parenchymal cells where it is metabolized, and evidence indicates vascular and non-vascular GLUTs are altered in AD brains, a process which could starve the brain of glucose and accelerate cognitive decline. Here we review the literature on glucose transport alterations in AD from human and rodent studies.Methods: Literature published between 1st January 1946 and 1st November 2020 within EMBASE and MEDLINE databases was searched for the terms “glucose transporters” AND “Alzheimer's disease”. Human and rodent studies were included while reviews, letters, and in-vitro studies were excluded.Results: Forty-three studies fitting the inclusion criteria were identified, covering human (23 studies) and rodent (20 studies). Post-mortem studies showed consistent reductions in GLUT1 and GLUT3 in the hippocampus and cortex of AD brains, areas of the brain closely associated with AD pathology. Tracer studies in rodent models of AD and human AD also exhibit reduced uptake of glucose and glucose-analogs into the brain, supporting these findings. Longitudinal rodent studies clearly indicate that changes in GLUT1 and GLUT3 only occur after amyloid-β pathology is present, and several studies indicate amyloid-β itself may be responsible for GLUT changes. Furthermore, evidence from human and rodent studies suggest GLUT depletion has severe effects on brain function. A small number of studies show GLUT2 and GLUT12 are increased in AD. Anti-diabetic medications improved glucose transport capacity in AD subjects.Conclusions: GLUT1 and GLUT3 are reduced in hippocampal and cortical regions in patients and rodent models of AD, and may be caused by high levels of amyloid-β in these regions. GLUT3 reductions appear to precede the onset of clinical symptoms. GLUT2 and GLUT12 appear to increase and may have a compensatory role. Repurposing anti-diabetic drugs to modify glucose transport shows promising results in human studies of AD.

1 February 2020 in Progress in Nuclear Magnetic Resonance Spectroscopy
Verified
Journal Article
Closed access
BDBen R. Dickie
Ben R. Dickie
GPGeoff Parker
Geoff Parker
LPLaura M. Parkes
Laura M. Parkes

28 November 2022 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Open access
PDF file
WHWilliam James Harris
William James Harris
MAMarie-Claude Asselin
Marie-Claude Asselin
RHRainer Hinz
Rainer Hinz
LPLaura Michelle Parkes
Laura Michelle Parkes
SAStuart Allan
Stuart Allan
BDBen Robert Dickie
Ben Robert Dickie
The blood–brain barrier (BBB) is the interface between the central nervous system and systemic circulation. It tightly regulates what enters and is removed from the brain parenchyma and is fundamental in maintaining brain homeostasis. Increasingly, the BBB is recognised as having a significant role in numerous neurological disorders, ranging from acute disorders (traumatic brain injury, stroke, seizures) to chronic neurodegeneration (Alzheimer’s disease, vascular dementia, small vessel disease). Numerous approaches have been developed to study the BBB in vitro, in vivo, and ex vivo. The complex multicellular structure and effects of disease are difficult to recreate accurately in vitro, and functional aspects of the BBB cannot be easily studied ex vivo. As such, the value of in vivo methods to study the intact BBB cannot be overstated. This review discusses the structure and function of the BBB and how these are affected in diseases. It then discusses in depth several established and novel methods for imaging the BBB in vivo, with a focus on MRI, nuclear imaging, and high-resolution intravital fluorescence microscopy.

1 January 2019 in NeuroImage
Verified
Journal Article
Closed access
BDBen R. Dickie
Ben R. Dickie
MVMatthias Vandesquille
Matthias Vandesquille
JUJosé Ulloa
José Ulloa
Hervé BoutinHervé Boutin
Hervé Boutin
LPLaura M. Parkes
Laura M. Parkes
GPGeoff Parker
Geoff Parker

15 March 2021 in NMR in Biomedicine
Verified
Journal Article
Open access
PDF file
BDBen R. Dickie
Ben R. Dickie
HBHervé Boutin
Hervé Boutin
GPGeoff Parker
Geoff Parker
LPLaura M. Parkes
Laura M. Parkes
The effects of Alzheimer's disease (AD) and ageing on blood–brain barrier (BBB) breakdown are investigated in TgF344‐AD and wild‐type rats aged 13, 18 and 21 months. Permeability surface area products of the BBB to water (PSw) and gadolinium‐based contrast agent (PSg) were measured in grey matter using multiflip angle multiecho dynamic contrast‐enhanced MRI. At 13 months of age, there was no significant difference in PSw between TgF344‐AD and wild‐types (p = 0.82). Between 13 and 18 months, PSw increased in TgF344‐AD rats (p = 0.027), but not in wild‐types (p = 0.99), leading to significantly higher PSw in TgF344‐AD rats at 18 months, as previously reported (p = 0.012). Between 18 and 21 months, PSw values increased in wild‐types (p = 0.050), but not in TgF344‐AD rats (p = 0.50). These results indicate that BBB water permeability is affected by both AD pathology and ageing, but that changes occur earlier in the presence of AD pathology. There were no significant genotype or ageing effects on PSg (p > 0.05). In conclusion, we detected increases in BBB water permeability with age in TgF344‐AD and wild‐type rats, and found that changes occurred at an earlier age in rats with AD pathology.

3 October 2024 in Journal of Cerebral Blood Flow & Metabolism
Verified
Journal Article
Open access
OJOlivia A Jones
Olivia A Jones
SMSaffwan Mohamed
Saffwan Mohamed
RHRainer Hinz
Rainer Hinz
APAlastair Paterson
Alastair Paterson
OSOluwaseun A Sobowale
Oluwaseun A Sobowale
APAdrian R Parry-Jones
Adrian R Parry-Jones
Neuroinflammation is a promising therapeutic target in intracerebral hemorrhage (ICH), characterized in the brain by microglial activation and blood-brain barrier (BBB) breakdown. In this study, 36 acute, spontaneous, supratentorial ICH patients underwent dynamic contrast-enhanced MRI to measure BBB permeability ( K trans ) 1–3 days post-onset and 16 returned for [ 11 C]( R )-PK11195 PET to quantify microglial activation ( BP ND ), 2–7 days post-onset. We first tested if these markers were increased and co-localized in the perihematomal brain and found that perihematomal K trans and BP ND were increased vs. the contralateral brain, but regions of high K trans and BP ND only overlapped by a mean of 4.9%. We then tested for associations of perihematomal K trans and BP ND with clinical characteristics (age, ICH volume & location, blood pressure), other markers of inflammation (edema, IL-6, and CRP), and long-term functional outcome (90-day mRS). Lower perihematomal BP ND was associated with increasing age. Lobar hemorrhage was associated with greater K trans than deep, but K trans and BP ND were not associated with ICH volume, or other inflammatory markers. While perihematomal K trans and BP ND were not associated with outcome, contralateral K trans was significantly associated with greater 90-day mRS. Exploratory analyses demonstrated that blood pressure variability over 72 h was also associated with contralateral K trans .